- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Dermata Therapeutics Inc. Warrant (DRMAW)

- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: DRMAW (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -33.33% | Avg. Invested days 10 | Today’s Advisory PASS |
Upturn Star Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.57 | 52 Weeks Range 0.01 - 0.03 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.03 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -95.9% | Return on Equity (TTM) -206.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 4154323 |
Shares Outstanding - | Shares Floating 4154323 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Dermata Therapeutics Inc. Warrant
Company Overview
History and Background
Dermata Therapeutics Inc. Warrant is a publicly traded security that represents the right, but not the obligation, to purchase shares of Dermata Therapeutics, Inc. at a specified price (the exercise price) before a certain expiration date. Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for dermatological diseases. The warrants were likely issued as part of a financing round, offering investors an additional potential upside if the company's stock price appreciates significantly. Specific details on founding year and significant milestones for the warrant itself are tied to the company's financing history.
Core Business Areas
- Dermatological Drug Development: Dermata Therapeutics focuses on developing small molecule therapeutics to address unmet medical needs in dermatology, with a primary focus on inflammatory and infectious skin diseases.
Leadership and Structure
The leadership and structure of Dermata Therapeutics Inc. Warrant are directly linked to Dermata Therapeutics, Inc. Information on the current executive team and board of directors can be found on Dermata Therapeutics, Inc.'s official investor relations pages.
Top Products and Market Share
Key Offerings
- Dermata Therapeutics, Inc. Pipeline: Dermata Therapeutics is developing a pipeline of novel small molecule drug candidates. Specific product details and clinical trial progress are subject to the company's ongoing research and development. Key competitors in the dermatology space include large pharmaceutical companies with established portfolios and other emerging biotechnology firms. Market share for individual pipeline candidates is not applicable until commercialization, but the overall dermatology market is substantial.
Market Dynamics
Industry Overview
The dermatology market is a significant and growing sector within the pharmaceutical industry, driven by an aging population, increasing awareness of skin health, and the development of new therapeutic modalities. It encompasses treatments for a wide range of conditions, including acne, psoriasis, eczema, and skin cancer.
Positioning
Dermata Therapeutics positions itself as a developer of innovative, small molecule therapeutics targeting unmet needs in dermatology. Its competitive advantage lies in its scientific approach and focus on specific disease mechanisms.
Total Addressable Market (TAM)
The global dermatology market is valued in the tens of billions of dollars and is projected to continue growing. Dermata Therapeutics aims to capture a share of this market with its specialized drug candidates. The TAM for specific indications within dermatology can also be substantial.
Upturn SWOT Analysis
Strengths
- Focus on unmet medical needs in dermatology
- Development of novel small molecule therapeutics
- Potential for significant upside if clinical trials are successful
Weaknesses
- Clinical trial risk and uncertainty
- Dependence on successful drug development and regulatory approval
- Limited operating history and potential for cash burn
Opportunities
- Growing global demand for dermatological treatments
- Partnership and collaboration opportunities with larger pharmaceutical companies
- Advancements in scientific understanding of skin diseases
Threats
- Competition from established and emerging players
- Regulatory hurdles and delays
- Failure to demonstrate efficacy or safety in clinical trials
- Market adoption challenges post-approval
Competitors and Market Share
Key Competitors
- AbbVie Inc. (ABBV)
- Eli Lilly and Company (LLY)
- Sanofi S.A. (SNY)
- Pfizer Inc. (PFE)
Competitive Landscape
Dermata Therapeutics operates in a highly competitive landscape. Larger, established pharmaceutical companies have significant resources, extensive marketing capabilities, and broad product portfolios. Dermata's advantage lies in its specialized focus and potential for breakthrough therapies in niche areas of dermatology. However, it faces challenges in R&D funding, clinical trial execution, and market penetration against these giants.
Growth Trajectory and Initiatives
Historical Growth: The historical growth trajectory of Dermata Therapeutics Inc. Warrant is dependent on the progress and market perception of Dermata Therapeutics, Inc.'s drug development pipeline. As a warrant, its value is derived from the underlying stock.
Future Projections: Future projections for Dermata Therapeutics Inc. Warrant are speculative and contingent upon the success of Dermata Therapeutics, Inc.'s clinical trials, regulatory approvals, and overall market sentiment towards the biotechnology sector and dermatological treatments. Analyst estimates for the underlying company's stock would be a key indicator.
Recent Initiatives: Recent initiatives for Dermata Therapeutics Inc. Warrant would be directly tied to Dermata Therapeutics, Inc.'s corporate actions, such as advancements in clinical trials, new research findings, or strategic partnerships.
Summary
Dermata Therapeutics Inc. Warrant is a speculative investment tied to the success of Dermata Therapeutics, Inc.'s drug development. The company operates in a large and growing dermatology market but faces significant clinical and regulatory risks. While it possesses potential for high returns if its pipeline is successful, it also carries substantial risk due to its early-stage status and competition from established players. Careful monitoring of clinical trial progress and financial health of the underlying company is crucial.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Financial news outlets
- Industry analysis reports
- Market data providers
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. The analysis is based on publicly available information and may not be exhaustive. Investing in warrants and early-stage biotechnology companies carries significant risk, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dermata Therapeutics Inc. Warrant
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-08-13 | Founder, President, CEO & Chairman Mr. Gerald T. Proehl | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.dermatarx.com |
Full time employees 8 | Website https://www.dermatarx.com | ||
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
Home 

